Homa Dastani

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella, Viktor Grünwald, Paul Nathan et al. · The Lancet Oncology · 2016 · 218 citations

Medicine, Nephrology, Oncology +13

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population

Joseph Menzin, Luke Boulanger, Jenő P. Marton et al. · Respiratory Medicine · 2008 · 118 citations

Medicine, Health Policy, Pharmacoeconomics +16

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Georgina V. Long, Victoria Atkinson, Paolo A. Ascierto et al. · Annals of Oncology · 2016 · 118 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Martin Reck, Fiona Taylor, John R. Penrod et al. · Journal of Thoracic Oncology · 2017 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14